drugset / Trial / NCT00505661
Letrozole in Patients With Ovarian Tumors
Non-randomizedSingle-groupOpen-labelTreatment
Summary
Primary Objectives: * To determine the objective response rate of Letrozole when administered to patients with advanced or recurrent borderline tumors or low-grade epithelial cancers from the ovary , fallopian tube or peritoneum. * To determine the time to tumor progression of patients with advanced or recurrent borderline tumors or low-grade epithelial cancers from the ovary, fallopian tube or peritoneum. * To identify the biological markers to predict response to Letrozole and study the aspects of the hormones in these types of tumors.
Timeline
- Start
- 2003-09
- Primary completion
- 2010-05
- Completion
- 2010-05
Outcome
Outcome not reported
Stopped (Enrollment): “Terminated due to slow patient accrual.”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Letrozole | Other / unclassified | 2.5 mg | Oral |